Highlights
• GSK secures US FDA Accelerated Approval for Nelkarmi in previously treated advanced ALK-positive lung cancer.
• The decision arrived ahead of the original FDA target action date of 27 November 2026.
• ALKOVE-1 data showed a 49% confirmed response rate in patients previously treated only with alectinib.
• Nelkarmi joined GSK's portfolio through the Acquisition of Nuvalent and is also in phase III testing.
"Designed to help address key challenges of ALK-positive non-small cell lung cancer" is how GSK (LSE:GSK) Chief Scientific Officer Tony Wood framed Nelkarmi, and the US Food and Drug Administration has now granted the medicine accelerated approval. The 18 November announcement puts a new oncology product into the hands of US doctors and gives the FTSE 100 drugmaker fresh momentum in lung cancer, one of the most closely studied areas of cancer care.
What the FDA has approved
Nelkarmi (neladalkib) is approved for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have previously received either one ALK tyrosine kinase inhibitor (TKI), alectinib, or two or more ALK TKIs plus platinum-based chemotherapy. The approval came ahead of the original target date of 27 November 2026. The medicine also holds FDA Breakthrough Therapy and Orphan Drug designations, both granted to medicines aimed at serious conditions or smaller patient populations with unmet needs.
Clinical data behind the decision
The approval draws on the phase I/II ALKOVE-1 trial. In patients previously treated only with alectinib, the confirmed overall response rate was 49% (33 of 67). In patients who had received two or more ALK TKIs and chemotherapy, it was 32% (50 of 155). Among patients with measurable central nervous system metastases, the intracranial response rate was 55% (11 of 20) in the alectinib-only group and 26% (14 of 53) in the group with two or more prior TKIs.
Safety profile and approval pathway
GSK (LSE:GSK) reported that the most common adverse reactions, seen in at least 20% of patients, were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, oedema and fatigue. Permanent discontinuation due to adverse reactions occurred in 5% of patients, most often linked to hepatotoxicity. As an accelerated approval, the decision rests on response rate data, a pathway under which the FDA can require further confirmatory evidence for continued approval.
How Nelkarmi fits GSK's oncology plans
Nelkarmi came into the group through the recent acquisition of Nuvalent, Inc. by GSK (LSE:GSK) Beyond today's indication, it is being studied in ALKAZAR, a phase III trial in patients with ALK-positive NSCLC who have not yet received a TKI, as well as in other solid tumours. ALK tyrosine kinase inhibitors are targeted medicines that act on the ALK protein that drives this form of lung cancer, and Nelkarmi is approved for use after earlier ALK-targeted treatment. That broader programme gives the medicine potential routes into earlier lines of treatment, subject to trial outcomes and regulatory review.
Milestones to track after the approval
The next markers sit in the clinic and in regulatory filings. Investors following LSE stocks in healthcare may look for updates on the ALKAZAR phase III trial, progress in other solid tumours and any submissions outside the US. Commercial launch details and future quarterly reporting should also show how the newly approved medicine is being introduced into US practice.
What accelerated approval means
Accelerated approval is a regulatory pathway that allows a medicine for a serious condition to be approved on the basis of a measure that is expected to predict clinical benefit, such as response rate, with further evidence required afterwards. In this case the decision rests on response rate data from the phase I/II ALKOVE-1 trial. The FDA can require confirmatory evidence for continued approval. Nelkarmi also holds Breakthrough Therapy and Orphan Drug designations, both granted to medicines aimed at serious conditions or smaller patient populations with unmet needs, and the approval came ahead of the original target action date of 27 November 2026.
Reading the trial results
Response rate is the share of patients whose tumours shrink by a defined amount. The confirmed overall response rate was 49% (33 of 67) in patients previously treated only with alectinib and 32% (50 of 155) in those who had received two or more ALK inhibitors and chemotherapy. Intracranial response rates, which measure shrinkage in the brain, were 55% (11 of 20) and 26% (14 of 53) in patients with measurable central nervous system metastases. The most common adverse reactions, seen in at least 20% of patients, included hepatotoxicity, musculoskeletal pain and fatigue, and permanent discontinuation due to adverse reactions occurred in 5% of patients. Further updates on the ALKAZAR phase III trial, which studies patients not yet treated with a TKI, will show whether the medicine can move into earlier lines of treatment.






Please wait processing your request...